# Caplin Point Laboratories (NSE: CAPLIPOINT) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CAPLIPOINT · Pivot · prices to 22 Oct 2026

Caplin Point Laboratories (NSE: CAPLIPOINT) closed at ₹2,227.80 on 22 Oct 2026, up 0.35% on the day. With a market capitalisation of ₹16,934 Cr, it ranks 388th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

Its return on equity was 19.3% in FY25. Over the past year the share price has risen 12.9%. Its 52-week range is ₹1,500.30 (30 Mar 2026) to ₹2,990.00 (24 Sep 2026); the last close is 25.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹600 Cr (+19.4% year on year) and net profit ₹173 Cr (+19.1%), on a consolidated basis. Promoters held 70.57% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,227.80 |
| Market cap | ₹16,934 Cr |
| ROE | 19.3% (FY25) |
| ROCE | 23.3% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹2,990.00 (24 Sep 2026) |
| 52-week low | ₹1,500.30 (30 Mar 2026) |
| 1-year return | +12.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹600 Cr | +19.4% | ₹173 Cr | +19.1% | ₹22.38 |
| Q3 FY26 | ₹543 Cr | +10.1% | ₹166 Cr | +18.4% | ₹21.56 |
| Q2 FY26 | ₹534 Cr | +10.5% | ₹160 Cr | +22.4% | ₹20.32 |
| Q1 FY26 | ₹510 Cr | +11.2% | ₹151 Cr | +20.7% | ₹20.10 |
| Q4 FY25 | ₹502 Cr | +10.9% | ₹145 Cr | +19.8% | ₹18.75 |
| Q3 FY25 | ₹493 Cr | +13.2% | ₹140 Cr | +16.9% | ₹18.28 |
| Q2 FY25 | ₹483 Cr | +17.8% | ₹131 Cr | +12.8% | ₹17.22 |
| Q1 FY25 | ₹459 Cr | +16.1% | ₹125 Cr | +19.9% | ₹16.32 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,937 Cr | ₹541 Cr |
| FY24 | ₹1,694 Cr | ₹461 Cr |
| FY23 | ₹1,467 Cr | ₹377 Cr |
| FY22 | ₹1,269 Cr | ₹308 Cr |
| FY21 | ₹1,061 Cr | ₹251 Cr |
| FY20 | ₹863 Cr | ₹215 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 70.57%
- Foreign institutions: 5.75%
- Domestic institutions: 2.49%
- Non-institutions: 21.18%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Cohance Lifesciences](https://app.pivotnow.in/stock/COHANCE) | ₹460.30 | ₹17,610 Cr | 98.6 | — |
| [Shilpa Medicare](https://app.pivotnow.in/stock/SHILPAMED) | ₹880.90 | ₹17,229 Cr | 70.9 | — |
| [Pfizer](https://app.pivotnow.in/stock/PFIZER) | ₹3,712.10 | ₹16,982 Cr | 23.5 | — |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,848 Cr | 25.3 | — |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,378.00 | ₹15,798 Cr | — | — |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,612 Cr | 27.7 | — |

## Questions and answers

### What is the share price of Caplin Point Laboratories today?

Caplin Point Laboratories (NSE: CAPLIPOINT) last closed at ₹2,227.80 on 22 Oct 2026. Its 52-week high is ₹2,990.00 and its 52-week low is ₹1,500.30.

### What is the market cap of Caplin Point Laboratories?

Caplin Point Laboratories' market capitalisation is ₹16,934 Cr (₹16,934 Cr) at the 22 Oct 2026 close, ranking 388th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Caplin Point Laboratories?

Return on equity was 19.3% in FY25 and return on capital employed was 23.3% in FY25 (consolidated figures).

### Is Caplin Point Laboratories a debt-free company?

Caplin Point Laboratories is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Caplin Point Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Caplin Point Laboratories reported revenue of ₹600 Cr, +19.4% year on year, and net profit of ₹173 Cr, +19.1% year on year.

### How has Caplin Point Laboratories stock performed over the last year?

Caplin Point Laboratories' share price has risen 12.9% over the past year, −10.6% over three months and −19.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Caplin Point Laboratories?

As of 30 Jun 2026: promoters 70.57%, foreign institutions 5.75%, domestic institutions 2.49%, non-institutions 21.18%.

### Who are Caplin Point Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Caplin Point Laboratories by market cap are Cohance Lifesciences, Shilpa Medicare, Pfizer, Eris Lifesciences, Onesource Specialty Pharma and Alivus Life Sciences.

### Is Caplin Point Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Caplin Point Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CAPLIPOINT against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.